Search

Displaying results 5321 - 5330 of 10000 in total
  1. Drug

    Zunsemetinib

    go.drugbank.com/drugs/DB16502
    Investigational

    Additionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. … Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis.

  2. Drug

    Isatoribine

    go.drugbank.com/drugs/DB04860
    Experimental

    Isatoribine is a selective agonist of TLR7.

  3. Drug

    Melperone

    go.drugbank.com/drugs/DB09224
    Investigational

    Melperone has been used for a span of greater than 30 years in the European Union [L1316]. … Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316].

    Products: MELPERON 1A PHARMA 50MG, MELPERON 1A PHARM 25MG/5ML
  4. Drug

    PF-08046040

    go.drugbank.com/drugs/DB17555
    Investigational

    SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody targeting CD70. … SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies).

  5. Drug

    EGEN-001

    go.drugbank.com/drugs/DB05953
    Investigational

    EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity

  6. Drug

    Amediplase

    go.drugbank.com/drugs/DB06679
    Experimental

    Amediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase.

  7. Drug

    Sitamaquine

    go.drugbank.com/drugs/DB04909
    Investigational

    Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential

  8. Drug

    LX6171

    go.drugbank.com/drugs/DB05180
    Investigational

    LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia

  9. Drug

    cAd3-Marburg vaccine

    go.drugbank.com/drugs/DB22520
    Investigational

    cAd3-Marburg vaccine is under investigation in clinical trial NCT06620003 (A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored

  10. Drug

    Cabiotraxetan

    go.drugbank.com/drugs/DB20465
    Experimental

    Cabiotraxetan has a monoisotopic molecular weight of 714.41 Da. … Cabiotraxetan is a small molecule drug. The usage of the INN stem '-xetan' in the name indicates that Cabiotraxetan is a chelating agent.